A vein bypass first versus a best endovascular treatment first revascularization strategy for patients with chronic limb-threatening ischaemia who require an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularization procedure to restore limb perfusion: the BASIL-2 within-trial health economic analysis
British Journal of Surgery · 2025
DOI: 10.1093/bjs/znaf119 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Surgery, 2025. Verfasst von Zainab Abdali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Endovascular Procedures, Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UK National Institute of Health Research, Health Technology Assessment.
Abstract (Originalsprache)
Background
Chronic limb-threatening ischaemia (CLTI) places a considerable socioeconomic burden health and social care systems worldwide. The objective of this health economic analysis was to investigate the cost-effectiveness (CEA) and cost-utility (CUA) of a vein bypass (VB) first versus a best endovascular treatment (BET) first revascularization strategy in patients with CLTI who require an infra-popliteal revascularization procedure to restore limb perfusion.
Methods
CEA and CUA analyses were conducted from the perspective of the UK National Health Service. Patient-level resource use and health outcomes data collected from the BASIL-2 trial over 2–7 years of follow-up were utilized to estimate incremental cost-effectiveness ratios expressed as cost per amputation-free life year (AFLY) and cost per quality-adjusted life year (QALY). EQ-5D-5L was used to generate participant QALYs at 2 and 3 years.
Results
At two years, the mean(s.d.) discounted hospital cost was £15 742.59(16 182.60) and £13 273.66(15 446.92) in the VB-first and BET-first revascularization strategy groups respectively. The lower costs (–£2524.23, 95% c.i., –£5844.93 to £1131.52) in the BET-first group were mainly due to the reduced number of days in hospital and lower procedural costs. BET-first was also more effective leading to additional AFLYs (0.429, 95% c.i., 0.03 to 0.88) at 7 years and discounted QALYs (0.016, 95% c.i., −0.08 to 0.12) at 2 years.
Conclusion
A best endovascular first revascularization strategy dominated a vein bypass first strategy in the cost-effectiveness and cost-utility analyses. The findings were robust across different scenarios and prespecified subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Birmingham Clinical Trial Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- University Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK.
- Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Black Country Vascular Network, Dudley Group of Hospitals, Dudley, UK.
ORCID-Profile: Matthew A Popplewell
Förderung
- UK National Institute of Health Research
- Health Technology Assessment
Zitieren
APA
Abdali, Z., Kigozi, J., Moakes, C. A., Bate, G. R., Hall, J., Kelly, L., Meecham, L., Bradbury, A. W., Popplewell, M. A., & BASIL-2 Investigators (2025). A vein bypass first versus a best endovascular treatment first revascularization strategy for patients with chronic limb-threatening ischaemia who require an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularization procedure to restore limb perfusion: the BASIL-2 within-trial health economic analysis. British Journal of Surgery. https://doi.org/10.1093/bjs/znaf119
Vancouver
Abdali Z, Kigozi J, Moakes CA, Bate GR, Hall J, Kelly L, et al. A vein bypass first versus a best endovascular treatment first revascularization strategy for patients with chronic limb-threatening ischaemia who require an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularization procedure to restore limb perfusion: the BASIL-2 within-trial health economic analysis. British Journal of Surgery. 2025. doi:10.1093/bjs/znaf119
BibTeX
@article{Abdali2025,
author = {Abdali, Zainab and Kigozi, Jesse and Moakes, Catherine A and Bate, Gareth R and Hall, Jack and Kelly, Lisa and Meecham, Lewis and Bradbury, Andrew W and Popplewell, Matthew A and BASIL-2 Investigators, BASIL-2 Investigators},
title = {A vein bypass first versus a best endovascular treatment first revascularization strategy for patients with chronic limb-threatening ischaemia who require an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularization procedure to restore limb perfusion: the BASIL-2 within-trial health economic analysis},
journal = {British Journal of Surgery},
year = {2025},
doi = {10.1093/bjs/znaf119}
}
EUVIMED